{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-052702","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.916507+00:00","generated_at":"2026-06-18T22:39:02.638026+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cytek Biosciences completes $46.5M acquisition of Luminex flow cytometry assets","bullets":["Closed acquisition of Luminex's flow cytometry and imaging business (Amnis, CellStream, Guava, Muse brands) on Feb 28, 2023.","Purchase price approximately $46.5 million in cash, subject to customary adjustments at closing.","Company assumed certain liabilities of the acquired business.","Financial statements and pro forma information to be filed within 71 days after this 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-052702","json":"https://secwatch.observer/filing/0001193125-23-052702.json","markdown":"https://secwatch.observer/filing/0001193125-23-052702.md","text":"https://secwatch.observer/filing/0001193125-23-052702.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523052702/0001193125-23-052702-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523052702/d331452d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:39:02.638026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90b08c0df035cbfc2d4f7a39897e273351f1b549","claim":"Cytek Biosciences, Inc. completed an acquisition involving Luminex Corporation for approximately $46.5 million in cash (closed 2023-02-28).","evidence_excerpt":"under the Purchase Agreement. Pursuant to the Purchase Agreement, as consideration for the FCI Acquisition, the Company paid an aggregate purchase price of approximately $46.5 million in cash, subject to certain customary adjustments at closing, and assumed certain liabilities of the Business. The foregoing description of the FCI Acquisition and the Purchase","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523052702/0001193125-23-052702-index.htm","confidence":1.0,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Luminex Corporation"},{"label":"Consideration","value":"approximately $46.5 million in cash"},{"label":"Closing","value":"2023-02-28"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}